Literature DB >> 22241908

Clinical significance of blood pressure ratios in hypertensive crisis in children.

Han-Ping Wu1, Wen-Chieh Yang, Yung-Kang Wu, Lu-Lu Zhao, Chun-Yu Chen, Yun-Ching Fu.   

Abstract

OBJECTIVES: Hypertensive crisis is categorised into hypertensive urgency and hypertensive emergency. The present work aimed to determine the effect of different gradings of blood pressure (BP) ratios in predicting the severity of paediatric hypertensive crisis.
METHODS: This was a retrospective case series, based in the paediatric emergency departments of the Changhua Christian Hospital and the Tzu-Chi General Hospital, Taiwan. From 1995 to 2010, the correlation between the severity of hypertension (HTN) and the difference in elevated systolic BP and 99th percentile plus 5 mm Hg (dSBP), the difference in elevated diastolic BP and 99th percentile plus 5 mm Hg (dDBP), dSBP ratio (dSBP/99th percentile plus 5 mm Hg) and dDBP ratio were analysed. A total of 110 children with a first attack of hypertensive crisis were recruited.
RESULTS: Patients with hypertensive crisis caused by essential HTN had lower dDBP ratios than the other causes (p=0.033), while those with an oncological aetiology had the highest dSBP and dDBP ratios among all the aetiologies. For clinical presentations, patients with nausea/vomiting and visual impairment presented with higher dSBP ratios than those without the symptoms (both p<0.05), but patients with altered consciousness had higher dSBP and dDBP ratios than those who had clear consciousness (p<0.05). Children with hypertensive urgency had lower dSBP and dDBP ratios than those with hypertensive emergency (both p<0.05).
CONCLUSIONS: dDBP and dSBP ratios may serve as BP parameters in predicting the severity of paediatric hypertensive crisis. A dSBP ratio greater than 20% may indicate a critical point for severe hypertensive crisis in children.

Entities:  

Mesh:

Year:  2012        PMID: 22241908     DOI: 10.1136/archdischild-2011-300373

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  8 in total

1.  The disulfide isomerase ERp57 is required for fibrin deposition in vivo.

Authors:  J Zhou; Y Wu; L Wang; L Rauova; V M Hayes; M Poncz; D W Essex
Journal:  J Thromb Haemost       Date:  2014-09-26       Impact factor: 5.824

Review 2.  Pediatric hypertensive emergencies.

Authors:  Rossana Baracco; Tej K Mattoo
Journal:  Curr Hypertens Rep       Date:  2014-08       Impact factor: 5.369

Review 3.  Evaluation and Management of Stage 2 Hypertension in Pediatric Patients.

Authors:  Yosuke Miyashita; Coral Hanevold
Journal:  Curr Hypertens Rep       Date:  2018-07-06       Impact factor: 5.369

4.  Clinical Characteristics of Hospitalized Pediatric Patients With Hypertensive Crisis-A Retrospective, Single-Center Study in China.

Authors:  Hongjun Ba; Huimin Peng; Lingling Xu; Youzhen Qin; Huisheng Wang
Journal:  Front Cardiovasc Med       Date:  2022-05-31

5.  Hypertensive crisis in children and adolescents.

Authors:  Tomáš Seeman; Gilad Hamdani; Mark Mitsnefes
Journal:  Pediatr Nephrol       Date:  2018-10-01       Impact factor: 3.714

6.  First-attack pediatric hypertensive crisis presenting to the pediatric emergency department.

Authors:  Wen-Chieh Yang; Lu-Lu Zhao; Chun-Yu Chen; Yung-Kang Wu; Yu-Jun Chang; Han-Ping Wu
Journal:  BMC Pediatr       Date:  2012-12-31       Impact factor: 2.125

Review 7.  Management of Hypertensive Crises in Children: A Review of the Recent Literature.

Authors:  Nicola Bertazza Partigiani; Rachele Spagnol; Laura Di Michele; Micaela Santini; Benedetta Grotto; Alex Sartori; Elita Zamperetti; Margherita Nosadini; Davide Meneghesso
Journal:  Front Pediatr       Date:  2022-04-15       Impact factor: 3.418

Review 8.  Hypertensive Crisis in Pediatric Patients: An Overview.

Authors:  Rupesh Raina; Zubin Mahajan; Aditya Sharma; Ronith Chakraborty; Sarisha Mahajan; Sidharth K Sethi; Gaurav Kapur; David Kaelber
Journal:  Front Pediatr       Date:  2020-10-20       Impact factor: 3.418

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.